Methotrexate microparticle encapsulated - Hubei Soundny Bio-Tech
Latest Information Update: 28 Aug 2023
At a glance
- Originator Hubei Soundny Bio-Tech CO., LTD
- Developer Hubei Soundny Bio-Tech; Xiangyang Central Hospital
- Class Abortifacients; Anti-inflammatories; Antiasthmatics; Antifibrotics; Antineoplastics; Antipsoriatics; Antirheumatics; Benzamides; Disease-modifying antirheumatics; Eye disorder therapies; Glutamates; Heart failure therapies; Pterins; Small molecules
- Mechanism of Action Antimetabolites; Immunosuppressants; Tetrahydrofolate dehydrogenase inhibitors; Thymidylate synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cholangiocarcinoma; Non-small cell lung cancer
Most Recent Events
- 28 Aug 2023 No recent reports of development identified for clinical-Phase-Unknown development in Cholangiocarcinoma in China
- 07 Jul 2020 Clinical trials in Cholangiocarcinoma in China, before July 2020 (unspecified route)
- 07 Jul 2020 Efficacy and adverse events data from a clinical trial in cholangiocarcinoma released by Hubei Soundny Biotechnology